Evidence map›Paper›PMID 39061796›Full record

ReviewBioengineering (Basel, Switzerland)2024

Prostate-Specific Membrane Antigen Radioligand Therapy in Non-Prostate Cancers: Where Do We Stand?

Francesco Dondi, Alberto Miceli, Guido Rovera, Vanessa Feudo, Claudia Battisti, Maria Rondini, Andrea Marongiu, Antonio Mura, Riccardo Camedda, Maria Silvia De Feo and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Bioengineering (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. [Frontiers in endocrinology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Francesco DondiNuclear Medicine Unit, ASST Spedali Civili di Brescia, 25123 Brescia, Italy.ORCID 0000-0003-4839-9033
Alberto MiceliNuclear Medicine Unit, Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy.
Guido RoveraNuclear Medicine Division, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
Vanessa FeudoUnit of Nuclear Medicine, Aosta Regional Hospital, 11100 Aosta, Italy.ORCID 0000-0001-9753-9472
Claudia BattistiSection of Nuclear Medicine, Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy.
Maria RondiniNuclear Medicine Unit, Fondazione Istituto G. Giglio, 90015 Cefalù, Italy.ORCID 0000-0003-1936-2848
Andrea MarongiuUnit of Nuclear Medicine, Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy.ORCID 0000-0001-7038-3615
Antonio MuraUnit of Nuclear Medicine, Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy.
Riccardo CameddaNuclear Medicine Unit, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", 00133 Rome, Italy.ORCID 0000-0003-0101-444X
Maria Silvia De FeoNuclear Medicine Unit, Department of Radiological Sciences, Oncology and Anatomo-Pathology, Sapienza University of Rome, 00185 Rome, Italy.ORCID 0000-0003-3216-4838
Miriam ConteNuclear Medicine Unit, Department of Radiological Sciences, Oncology and Anatomo-Pathology, Sapienza University of Rome, 00185 Rome, Italy.ORCID 0000-0002-1677-4858
Joana GoricaNuclear Medicine Unit, Department of Radiological Sciences, Oncology and Anatomo-Pathology, Sapienza University of Rome, 00185 Rome, Italy.
Cristina FerrariSection of Nuclear Medicine, Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy.ORCID 0000-0002-0168-8551
Anna Giulia NappiSection of Nuclear Medicine, Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy.ORCID 0000-0002-9046-6378
Giulia SantoNuclear Medicine Unit, Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy.ORCID 0000-0001-6565-0686

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe term theragnostic refers to the combination of a predictive imaging biomarker with a therapeutic agent. The promising application of prostate-specific membrane antigen (PSMA)-based radiopharmaceuticals in the imaging and treatment of prostate cancer (PCa) patients opens the way to investigate a possible role of PSMA-based radiopharmaceuticals in cancers beyond the prostate. Therefore, the aim of this review was to evaluate the role of

methodsAn extensive literature search was performed in three different databases using different combinations of the following terms: "Lu-PSMA", "

resultsA total of four preclinical studies were selected (breast cancer model

conclusionsThe need for larger patient cohorts and more RLT cycles administered underscores the need for further comprehensive studies. Given the very preliminary results of both preclinical and clinical studies, ongoing clinical trials in the near future may provide stronger evidence of both the safety and therapeutic efficacy of PSMA-RLT in malignancies other than prostate cancer.

Indexed as

luthetium-177non-prostatePSMAradioligand therapysolid tumours

Identifiers

PMID39061796
PMCPMC11273965

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.